Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Aspirin's secret weapon against preeclampsia? immune cells under the microscope

NCT ID NCT04974892

Knowledge-focused Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study investigated why low-dose aspirin helps prevent preeclampsia in some high-risk pregnant women but not others. Researchers took blood samples from 35 women at four points during pregnancy to study their immune cells, particularly neutrophils. The goal was to identify differences between women who responded to aspirin and those who still developed preeclampsia, which could lead to better prevention strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help explain why low-dose aspirin prevents preeclampsia in some high-risk women but not others, potentially leading to better prevention strategies.
What could go wrong
This is a small observational study (35 participants) that only looks at immune markers, not a treatment trial. The findings may not apply to all women or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

35 people

The number who actually took part.

Started

Apr 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients at high risk of developing preeclampsia in pregnancy who are started on low dose aspirin at ≤16 weeks.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age 18-60 years * Singleton pregnancy * Live fetus at 11-13 weeks of gestation * Informed, written consent * Upper age of 60 years * Patient taking low dose aspirin as standard of care Exclusion criteria * Unwilling or unable to give consent * Participants who are unable to understand written English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immunology are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

immune system disorder preeclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immunology Neutrophil Preeclampsia Pregnancy

Contacts and locations

Locations

  • Barts Health NHS Trust, The Royal London Hospital

    London, E1 1BB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.